Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biocept Inc
(NQ:
BIOC
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 24, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biocept Inc
< Previous
1
2
3
Next >
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
September 21, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
September 08, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Inc. (NASDAQ: BIOC) Near the Top of Equities by Percentage Gain on 5/19
May 19, 2023
Via
Investor Brand Network
Biocept to Participate in the H.C. Wainwright Global Investment Conference
September 05, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept to Hold Business Update Conference Call on August 30, 2023
August 25, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
August 14, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Announces the Passing of Board Chair M. Faye Wilson
July 13, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Names Antonino Morales as President and Chief Executive Officer
June 20, 2023
From
Biocept, Inc.
Via
Business Wire
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology
June 05, 2023
From
Biocept, Inc.
Via
Business Wire
BioMedNewsBreaks – Biocept Inc. (NASDAQ: BIOC) Releases Pricing on Public Offering
June 01, 2023
Via
Investor Brand Network
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
May 24, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Announces One-for-Thirty Reverse Stock Split
May 17, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Reports First Quarter 2023 Financial Results
May 10, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Reports 2022 Financial Results
April 17, 2023
From
Biocept, Inc.
Via
Business Wire
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases
March 24, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
January 06, 2023
From
Biocept, Inc.
Via
Business Wire
Biocept Reports Third Quarter 2022 Financial Results
November 21, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
November 18, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
November 16, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Reports Second Quarter 2022 Financial Results
November 10, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept to Present at the LD Micro Main Event XV
October 19, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
October 17, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
October 14, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
October 06, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
August 22, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
August 16, 2022
From
Biocept, Inc.
Via
Business Wire
Biocept Appoints RSM as Independent Auditor
June 27, 2022
From
Biocept, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.